INM
Price
$3.38
Change
-$0.08 (-2.31%)
Updated
Jun 27 closing price
Capitalization
4.13M
MDXG
Price
$5.94
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
877.35M
37 days until earnings call
Interact to see
Advertisement

INM vs MDXG

Header iconINM vs MDXG Comparison
Open Charts INM vs MDXGBanner chart's image
InMed Pharmaceuticals
Price$3.38
Change-$0.08 (-2.31%)
Volume$257.8K
Capitalization4.13M
MiMedx Group
Price$5.94
Change-$0.00 (-0.00%)
Volume$1.99M
Capitalization877.35M
INM vs MDXG Comparison Chart in %
Loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INM vs. MDXG commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INM is a Hold and MDXG is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (INM: $3.38 vs. MDXG: $5.94)
Brand notoriety: INM and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INM: 6% vs. MDXG: 279%
Market capitalization -- INM: $4.13M vs. MDXG: $877.35M
INM [@Biotechnology] is valued at $4.13M. MDXG’s [@Biotechnology] market capitalization is $877.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INM’s FA Score shows that 0 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • INM’s FA Score: 0 green, 5 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, MDXG is a better buy in the long-term than INM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INM’s TA Score shows that 6 TA indicator(s) are bullish while MDXG’s TA Score has 4 bullish TA indicator(s).

  • INM’s TA Score: 6 bullish, 3 bearish.
  • MDXG’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, INM is a better buy in the short-term than MDXG.

Price Growth

INM (@Biotechnology) experienced а +35.74% price change this week, while MDXG (@Biotechnology) price change was +2.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

MDXG is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDXG($877M) has a higher market cap than INM($4.13M). MDXG has higher P/E ratio than INM: MDXG (22.00) vs INM (0.01). INM YTD gains are higher at: -26.362 vs. MDXG (-38.254). MDXG has higher annual earnings (EBITDA): 62.1M vs. INM (-7.86M). MDXG has more cash in the bank: 106M vs. INM (4.68M). INM has less debt than MDXG: INM (849K) vs MDXG (18.7M). MDXG has higher revenues than INM: MDXG (352M) vs INM (4.92M).
INMMDXGINM / MDXG
Capitalization4.13M877M0%
EBITDA-7.86M62.1M-13%
Gain YTD-26.362-38.25469%
P/E Ratio0.0122.000%
Revenue4.92M352M1%
Total Cash4.68M106M4%
Total Debt849K18.7M5%
FUNDAMENTALS RATINGS
INM vs MDXG: Fundamental Ratings
INM
MDXG
OUTLOOK RATING
1..100
9963
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
10082
SMR RATING
1..100
9841
PRICE GROWTH RATING
1..100
4185
P/E GROWTH RATING
1..100
8212
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (40) in the null industry is in the same range as MDXG (66) in the Biotechnology industry. This means that INM’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as INM (100) in the null industry. This means that MDXG’s stock grew similarly to INM’s over the last 12 months.

MDXG's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for INM (98) in the null industry. This means that MDXG’s stock grew somewhat faster than INM’s over the last 12 months.

INM's Price Growth Rating (41) in the null industry is somewhat better than the same rating for MDXG (85) in the Biotechnology industry. This means that INM’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for INM (82) in the null industry. This means that MDXG’s stock grew significantly faster than INM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMMDXG
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPFCX19.650.15
+0.77%
PGIM Jennison Focused Growth C
TNRAX19.310.14
+0.73%
1290 Avantis U.S. Large Cap Growth A
FSJHX82.000.47
+0.58%
Fidelity Advisor Stock Sel M
EAPDX15.730.03
+0.19%
Parametric Dividend Income A
IHSVX28.830.02
+0.07%
Hartford Small Company R6

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with OMER. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then OMER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
-2.31%
OMER - INM
46%
Loosely correlated
-3.61%
TTNP - INM
43%
Loosely correlated
-1.79%
SPHDF - INM
33%
Poorly correlated
N/A
XFOR - INM
32%
Poorly correlated
-8.50%
SQZB - INM
29%
Poorly correlated
N/A
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with INM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then INM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
N/A
INM - MDXG
38%
Loosely correlated
-2.31%
PCVX - MDXG
36%
Loosely correlated
-0.91%
OMER - MDXG
36%
Loosely correlated
-3.61%
MGNX - MDXG
34%
Loosely correlated
-6.30%
CTMX - MDXG
32%
Poorly correlated
-2.60%
More